The TGA has urged doctors to be vigilant for diabetic ketoacidosis in patients taking sodium glucose co-transporter inhibitors). The safety notice applies to drugs such as dapagliflozin (Forxiga, Xigduo XR), canagliflozin (Invokana) and empagliflozin (Jardiance). The presentation of DKA was sometimes atypical and glucose levels in some cases were only mildly elevated at less than 11 mmol/L ...
Type 2 diabetes
Diabetic ketoacidosis warning for SGLT2 inhibitors
17 Aug 2015